Study type

Study type

Non-interventional study

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Non-Interventional Study
Study drug and medical condition

Name of medicine

SCENESSE

Medical condition to be studied

Porphyria non-acute
Population studied

Age groups

Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)

Estimated number of subjects

200
Study design details

Main study objective

The study has been designed to assess whether SCENESSE® can be used safely within porphyria treatment centres and to generate data on long term safety and outcome endpoints derived from the use of SCENESSE®. The recommended risk minimization measures and the effectiveness of the controlled distribution of SCENESSE® will also be assessed.

Outcomes

Gather long-term safety data on SCENESSE®, Evaluate compliance with the risk minimization measures

Data analysis plan

Safety assessment as outlined above will occur via the European EPP Disease Registry. Treatment-emergent adverse events and the use of concomitant medications will be assessed at every visit to the treatment centre and recorded using electronic CRFs. Compliance with the risk minimization measures will be assessed against the designated criteria throughout the study while the effectiveness of the controlled distribution of SCENESSE® will be evaluated every 12 months.Analysis of Clinical EffectivenessAll patients enrolled in the registry will be included in the assessment of clinical effectiveness so long as data are available. In general, baseline will be the data recorded on entry into the Registry. In general, clinical effectiveness will also be summarised by the subgroup variables, SCENESSE exposure at entry and Season of enrolment.